The estimated Net Worth of George B Abercrombie is at least $1.8 Million dollars as of 18 April 2022. Mr. Abercrombie owns over 5,000 units of Biocryst Pharmaceuticals stock worth over $38,650 and over the last 15 years he sold BCRX stock worth over $1,634,871. In addition, he makes $129,713 as Independent Director at Biocryst Pharmaceuticals.
George has made over 15 trades of the Biocryst Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of BCRX stock worth $16,600 on 18 April 2022.
The largest trade he's ever made was selling 74,000 units of Biocryst Pharmaceuticals stock on 10 September 2021 worth over $1,116,660. On average, George trades about 3,532 units every 77 days since 2010. As of 18 April 2022 he still owns at least 5,000 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Abercrombie stock trades at the bottom of the page.
George B. Abercrombie serves as Independent Director of the Company. Mr. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. Mr. Abercrombie held the position of Senior Vice President and Chief Commercial Officer at Innoviva, Inc., a publicly traded bio-pharmaceutical asset management company, from 2014 to 2018. He served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie also serves on the Board of Brickell Biotech, a private pharmaceutical company. He formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc., Ziopharm Oncology, Inc, Tranzyme Pharma, Aptus Health, Inc. and DemeRX. Additionally, he is an Adjunct Professor at Duke University’s Fuqua School of Business and a board member of the North Carolina GlaxoSmithKline Foundation. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Pub.
As the Independent Director of Biocryst Pharmaceuticals, the total compensation of George Abercrombie at Biocryst Pharmaceuticals is $129,713. There are 12 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
George Abercrombie is 65, he's been the Independent Director of Biocryst Pharmaceuticals since 2017. There are 7 older and 14 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
George's mailing address filed with the SEC is PO BOX 16069, , CHAPEL HILL, NC, 27516.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... und Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: